| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Tubules, Proximal | 14 | 2026 | 26 | 3.110 |
Why?
|
| Models, Biological | 9 | 2026 | 1217 | 2.860 |
Why?
|
| Kidney Diseases | 5 | 2025 | 180 | 2.270 |
Why?
|
| Organoids | 3 | 2025 | 45 | 1.990 |
Why?
|
| Kidney | 11 | 2026 | 456 | 1.730 |
Why?
|
| Testis | 2 | 2025 | 162 | 1.730 |
Why?
|
| Toxicity Tests | 4 | 2025 | 19 | 1.710 |
Why?
|
| Acute Kidney Injury | 5 | 2025 | 143 | 1.520 |
Why?
|
| Lab-On-A-Chip Devices | 4 | 2026 | 25 | 1.410 |
Why?
|
| Intestinal Mucosa | 4 | 2025 | 249 | 1.370 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2025 | 151 | 1.150 |
Why?
|
| Drug Evaluation, Preclinical | 6 | 2025 | 99 | 1.130 |
Why?
|
| Syndecan-1 | 2 | 2024 | 9 | 1.080 |
Why?
|
| Corneal Dystrophies, Hereditary | 3 | 2017 | 3 | 1.060 |
Why?
|
| Retinal Diseases | 3 | 2017 | 32 | 1.000 |
Why?
|
| Liver | 11 | 2020 | 878 | 0.990 |
Why?
|
| Plasma | 2 | 2024 | 39 | 0.960 |
Why?
|
| Genitalia, Male | 1 | 2025 | 11 | 0.950 |
Why?
|
| Cytochrome P-450 CYP3A | 5 | 2024 | 11 | 0.950 |
Why?
|
| Wounds and Injuries | 5 | 2025 | 261 | 0.910 |
Why?
|
| Reproduction | 1 | 2025 | 100 | 0.900 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2024 | 631 | 0.890 |
Why?
|
| Trauma Centers | 6 | 2022 | 132 | 0.890 |
Why?
|
| Pharmaceutical Preparations | 6 | 2026 | 122 | 0.840 |
Why?
|
| Sequence Analysis, RNA | 1 | 2025 | 182 | 0.830 |
Why?
|
| Burns | 1 | 2024 | 45 | 0.820 |
Why?
|
| Resuscitation | 1 | 2024 | 73 | 0.810 |
Why?
|
| Epithelial Cells | 7 | 2026 | 419 | 0.810 |
Why?
|
| Cytochrome P-450 Enzyme System | 5 | 2021 | 28 | 0.730 |
Why?
|
| Membrane Transport Proteins | 5 | 2025 | 139 | 0.720 |
Why?
|
| Drug Discovery | 3 | 2021 | 100 | 0.700 |
Why?
|
| Cytochrome P450 Family 4 | 4 | 2021 | 4 | 0.680 |
Why?
|
| Humans | 73 | 2026 | 65534 | 0.680 |
Why?
|
| Prescription Drugs | 1 | 2021 | 51 | 0.670 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2024 | 67 | 0.670 |
Why?
|
| Ochratoxins | 1 | 2020 | 1 | 0.670 |
Why?
|
| Disease Models, Animal | 3 | 2024 | 2294 | 0.650 |
Why?
|
| Traumatology | 3 | 2025 | 15 | 0.630 |
Why?
|
| Animals | 25 | 2026 | 21533 | 0.630 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2021 | 149 | 0.610 |
Why?
|
| Biomarkers | 7 | 2025 | 1473 | 0.600 |
Why?
|
| Polymyxins | 1 | 2018 | 1 | 0.590 |
Why?
|
| Rats | 9 | 2025 | 2018 | 0.560 |
Why?
|
| Biological Transport | 8 | 2025 | 295 | 0.550 |
Why?
|
| Cell Culture Techniques | 6 | 2020 | 195 | 0.550 |
Why?
|
| Drug Interactions | 4 | 2026 | 127 | 0.540 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2017 | 35 | 0.510 |
Why?
|
| Life Support Care | 1 | 2017 | 20 | 0.510 |
Why?
|
| Renal Elimination | 1 | 2016 | 3 | 0.500 |
Why?
|
| General Surgery | 3 | 2016 | 215 | 0.490 |
Why?
|
| Forecasting | 1 | 2017 | 232 | 0.490 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 537 | 0.490 |
Why?
|
| Intestinal Absorption | 3 | 2025 | 33 | 0.490 |
Why?
|
| Respiratory Insufficiency | 1 | 2017 | 156 | 0.440 |
Why?
|
| Cell Line | 8 | 2021 | 2068 | 0.400 |
Why?
|
| Computer Simulation | 3 | 2026 | 487 | 0.390 |
Why?
|
| DNA | 2 | 2017 | 855 | 0.380 |
Why?
|
| Mutation | 2 | 2021 | 2680 | 0.380 |
Why?
|
| Space Flight | 2 | 2022 | 20 | 0.370 |
Why?
|
| Male | 28 | 2025 | 31065 | 0.360 |
Why?
|
| Ichthyosis, Lamellar | 1 | 2011 | 1 | 0.350 |
Why?
|
| Cisplatin | 3 | 2020 | 149 | 0.340 |
Why?
|
| Hepatocytes | 5 | 2020 | 225 | 0.330 |
Why?
|
| Zinc | 1 | 2011 | 95 | 0.320 |
Why?
|
| Cell Differentiation | 2 | 2025 | 1394 | 0.310 |
Why?
|
| Emergency Medicine | 1 | 2012 | 195 | 0.310 |
Why?
|
| Hepatitis A Virus Cellular Receptor 1 | 2 | 2019 | 3 | 0.300 |
Why?
|
| Education, Medical, Graduate | 1 | 2012 | 352 | 0.300 |
Why?
|
| Cytochrome P-450 CYP2D6 | 4 | 2016 | 7 | 0.290 |
Why?
|
| Hypoglycemic Agents | 2 | 2025 | 224 | 0.280 |
Why?
|
| Metformin | 2 | 2025 | 76 | 0.280 |
Why?
|
| Blood-Brain Barrier | 2 | 2023 | 87 | 0.280 |
Why?
|
| Critical Care | 2 | 2025 | 410 | 0.270 |
Why?
|
| Intestine, Small | 2 | 2020 | 82 | 0.270 |
Why?
|
| Intestinal Obstruction | 2 | 2019 | 53 | 0.260 |
Why?
|
| Heme Oxygenase-1 | 2 | 2018 | 20 | 0.260 |
Why?
|
| Administration, Oral | 2 | 2025 | 376 | 0.260 |
Why?
|
| Emergencies | 3 | 2019 | 123 | 0.260 |
Why?
|
| Benzalkonium Compounds | 1 | 2026 | 5 | 0.250 |
Why?
|
| Anti-Bacterial Agents | 3 | 2023 | 821 | 0.250 |
Why?
|
| Endothelium, Vascular | 2 | 2024 | 178 | 0.250 |
Why?
|
| Pharmacokinetics | 1 | 2026 | 7 | 0.240 |
Why?
|
| Organic Anion Transporters | 2 | 2023 | 6 | 0.240 |
Why?
|
| Cells, Cultured | 8 | 2026 | 2214 | 0.240 |
Why?
|
| Terpenes | 2 | 2016 | 30 | 0.230 |
Why?
|
| Pregnancy | 5 | 2019 | 2432 | 0.230 |
Why?
|
| RNA, Messenger | 6 | 2025 | 1587 | 0.230 |
Why?
|
| Drug Repositioning | 1 | 2025 | 10 | 0.230 |
Why?
|
| Female | 28 | 2025 | 34113 | 0.230 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 2 | 2015 | 11 | 0.220 |
Why?
|
| Thrombomodulin | 1 | 2024 | 17 | 0.220 |
Why?
|
| Enterocytes | 1 | 2024 | 25 | 0.220 |
Why?
|
| Glycocalyx | 1 | 2024 | 3 | 0.210 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 2 | 2021 | 44 | 0.210 |
Why?
|
| Shock | 1 | 2024 | 33 | 0.210 |
Why?
|
| Single-Cell Analysis | 1 | 2025 | 127 | 0.210 |
Why?
|
| Precision Medicine | 1 | 2025 | 127 | 0.210 |
Why?
|
| Microsomes, Liver | 2 | 2021 | 21 | 0.200 |
Why?
|
| Stem Cells | 1 | 2025 | 274 | 0.200 |
Why?
|
| Kidney Tubules | 2 | 2022 | 22 | 0.190 |
Why?
|
| Pneumococcal Infections | 1 | 2022 | 39 | 0.190 |
Why?
|
| Weightlessness | 1 | 2022 | 12 | 0.190 |
Why?
|
| Gentamicins | 2 | 2019 | 25 | 0.190 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2022 | 16 | 0.190 |
Why?
|
| Pilots | 1 | 2022 | 10 | 0.190 |
Why?
|
| Surgical Procedures, Operative | 3 | 2015 | 144 | 0.190 |
Why?
|
| Cystic Fibrosis | 1 | 2023 | 127 | 0.190 |
Why?
|
| Hospitals, Community | 1 | 2022 | 72 | 0.190 |
Why?
|
| Hepatitis C | 2 | 2016 | 153 | 0.180 |
Why?
|
| Polymyxin B | 2 | 2018 | 11 | 0.180 |
Why?
|
| Air Ambulances | 1 | 2022 | 32 | 0.180 |
Why?
|
| Middle Aged | 15 | 2024 | 18261 | 0.180 |
Why?
|
| Mice | 7 | 2025 | 11209 | 0.180 |
Why?
|
| Appendicitis | 1 | 2022 | 84 | 0.180 |
Why?
|
| Xenobiotics | 2 | 2018 | 13 | 0.180 |
Why?
|
| Cytokines | 1 | 2025 | 956 | 0.180 |
Why?
|
| G-Quadruplexes | 1 | 2021 | 6 | 0.170 |
Why?
|
| Morpholinos | 1 | 2021 | 52 | 0.170 |
Why?
|
| Aldehyde Oxidase | 1 | 2020 | 1 | 0.170 |
Why?
|
| Adult | 16 | 2025 | 17409 | 0.170 |
Why?
|
| HEK293 Cells | 2 | 2021 | 630 | 0.170 |
Why?
|
| Glucuronosyltransferase | 1 | 2020 | 11 | 0.170 |
Why?
|
| Sulfotransferases | 1 | 2020 | 9 | 0.170 |
Why?
|
| Cell Survival | 3 | 2018 | 600 | 0.170 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2020 | 11 | 0.170 |
Why?
|
| Organic Cation Transport Proteins | 3 | 2020 | 4 | 0.170 |
Why?
|
| Postoperative Complications | 3 | 2022 | 1326 | 0.170 |
Why?
|
| Membrane Proteins | 2 | 2016 | 929 | 0.160 |
Why?
|
| Vitamin D | 2 | 2018 | 140 | 0.160 |
Why?
|
| Flame Retardants | 1 | 2020 | 6 | 0.160 |
Why?
|
| Halogenated Diphenyl Ethers | 1 | 2020 | 9 | 0.160 |
Why?
|
| Intestines | 1 | 2021 | 176 | 0.160 |
Why?
|
| Renal Reabsorption | 1 | 2019 | 1 | 0.160 |
Why?
|
| Drug Antagonism | 1 | 2019 | 9 | 0.160 |
Why?
|
| United States | 7 | 2025 | 8130 | 0.160 |
Why?
|
| Desogestrel | 1 | 2019 | 4 | 0.160 |
Why?
|
| Benzoxazines | 1 | 2019 | 11 | 0.160 |
Why?
|
| Levonorgestrel | 1 | 2019 | 10 | 0.160 |
Why?
|
| Tissue Culture Techniques | 1 | 2019 | 35 | 0.160 |
Why?
|
| Surgeons | 1 | 2022 | 184 | 0.160 |
Why?
|
| Iohexol | 1 | 2019 | 18 | 0.150 |
Why?
|
| Gene Expression Profiling | 2 | 2020 | 801 | 0.150 |
Why?
|
| Contraceptive Agents, Female | 1 | 2019 | 24 | 0.150 |
Why?
|
| Retrospective Studies | 8 | 2024 | 6880 | 0.150 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 189 | 0.150 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2019 | 5 | 0.150 |
Why?
|
| Critical Pathways | 1 | 2019 | 33 | 0.150 |
Why?
|
| Rifampin | 1 | 2019 | 25 | 0.150 |
Why?
|
| Digestive System Diseases | 1 | 2019 | 14 | 0.150 |
Why?
|
| Dehydrocholesterols | 1 | 2018 | 1 | 0.150 |
Why?
|
| Desmosterol | 1 | 2018 | 2 | 0.150 |
Why?
|
| Lanosterol | 1 | 2018 | 4 | 0.150 |
Why?
|
| Aged | 14 | 2024 | 14941 | 0.150 |
Why?
|
| Emergency Medical Services | 1 | 2022 | 272 | 0.150 |
Why?
|
| Microsomes | 2 | 2016 | 11 | 0.140 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-2 | 1 | 2018 | 2 | 0.140 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2018 | 33 | 0.140 |
Why?
|
| Anti-HIV Agents | 1 | 2019 | 146 | 0.140 |
Why?
|
| Hospital Mortality | 4 | 2016 | 879 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 880 | 0.140 |
Why?
|
| Gene Expression | 2 | 2018 | 867 | 0.140 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 46 | 0.140 |
Why?
|
| Myocardium | 1 | 2020 | 298 | 0.140 |
Why?
|
| Lymphoma | 1 | 2019 | 103 | 0.140 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2019 | 90 | 0.140 |
Why?
|
| Enteral Nutrition | 1 | 2018 | 55 | 0.140 |
Why?
|
| Aristolochic Acids | 1 | 2017 | 1 | 0.140 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2018 | 134 | 0.140 |
Why?
|
| Graft vs Host Disease | 1 | 2019 | 115 | 0.140 |
Why?
|
| Lung | 2 | 2020 | 972 | 0.140 |
Why?
|
| RNA, Long Noncoding | 1 | 2020 | 172 | 0.130 |
Why?
|
| Hydrocortisone | 1 | 2019 | 194 | 0.130 |
Why?
|
| Electroretinography | 1 | 2017 | 26 | 0.130 |
Why?
|
| Fundus Oculi | 1 | 2017 | 26 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 524 | 0.130 |
Why?
|
| Genes, Recessive | 1 | 2017 | 54 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 197 | 0.130 |
Why?
|
| Homozygote | 1 | 2017 | 125 | 0.130 |
Why?
|
| Fluorescein Angiography | 1 | 2017 | 63 | 0.130 |
Why?
|
| Referral and Consultation | 2 | 2022 | 434 | 0.130 |
Why?
|
| Patient Admission | 2 | 2016 | 199 | 0.130 |
Why?
|
| Tissue Engineering | 1 | 2018 | 147 | 0.130 |
Why?
|
| Pedigree | 1 | 2017 | 199 | 0.130 |
Why?
|
| Specialties, Surgical | 1 | 2017 | 46 | 0.130 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 198 | 0.130 |
Why?
|
| Contrast Media | 1 | 2019 | 433 | 0.130 |
Why?
|
| Kidney Cortex | 1 | 2016 | 10 | 0.130 |
Why?
|
| Hepatitis C, Chronic | 1 | 2017 | 91 | 0.130 |
Why?
|
| Glucuronides | 1 | 2016 | 10 | 0.130 |
Why?
|
| Biological Transport, Active | 1 | 2016 | 38 | 0.130 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2017 | 53 | 0.120 |
Why?
|
| Visual Acuity | 1 | 2017 | 134 | 0.120 |
Why?
|
| Hospitals, Low-Volume | 1 | 2016 | 20 | 0.120 |
Why?
|
| Metoprolol | 1 | 2015 | 17 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 358 | 0.120 |
Why?
|
| Health Services for the Aged | 1 | 2016 | 49 | 0.120 |
Why?
|
| Blood Loss, Surgical | 1 | 2016 | 65 | 0.120 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2017 | 184 | 0.120 |
Why?
|
| Hospitals, High-Volume | 1 | 2016 | 33 | 0.120 |
Why?
|
| Patient Care Planning | 1 | 2016 | 83 | 0.120 |
Why?
|
| Homeostasis | 1 | 2018 | 376 | 0.120 |
Why?
|
| Proteome | 1 | 2016 | 160 | 0.110 |
Why?
|
| Erythrocyte Transfusion | 1 | 2016 | 78 | 0.110 |
Why?
|
| Lactation | 1 | 2015 | 77 | 0.110 |
Why?
|
| Geriatric Assessment | 1 | 2016 | 161 | 0.110 |
Why?
|
| State Government | 1 | 2015 | 33 | 0.110 |
Why?
|
| Ultrasonography | 1 | 2017 | 495 | 0.110 |
Why?
|
| Hemorrhage | 1 | 2017 | 280 | 0.110 |
Why?
|
| Glyburide | 1 | 2014 | 9 | 0.110 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2015 | 152 | 0.110 |
Why?
|
| Biocatalysis | 1 | 2015 | 50 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2022 | 816 | 0.110 |
Why?
|
| Proline | 1 | 2015 | 49 | 0.110 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 311 | 0.110 |
Why?
|
| Morbidity | 1 | 2015 | 111 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 2510 | 0.110 |
Why?
|
| Liver Cirrhosis | 1 | 2016 | 182 | 0.110 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2014 | 41 | 0.110 |
Why?
|
| Venous Thromboembolism | 1 | 2016 | 148 | 0.110 |
Why?
|
| Survival Rate | 1 | 2017 | 861 | 0.110 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2016 | 95 | 0.110 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2016 | 182 | 0.110 |
Why?
|
| Cell Membrane | 1 | 2016 | 510 | 0.100 |
Why?
|
| Substrate Specificity | 2 | 2012 | 344 | 0.100 |
Why?
|
| Models, Animal | 2 | 2012 | 241 | 0.100 |
Why?
|
| Phenotype | 1 | 2017 | 1241 | 0.100 |
Why?
|
| Blotting, Western | 1 | 2014 | 619 | 0.100 |
Why?
|
| Ethanol | 1 | 2016 | 330 | 0.100 |
Why?
|
| Aged, 80 and over | 6 | 2022 | 5608 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 3 | 2016 | 3468 | 0.090 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2013 | 119 | 0.090 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2025 | 38 | 0.090 |
Why?
|
| Accreditation | 1 | 2012 | 77 | 0.090 |
Why?
|
| Lipids | 1 | 2014 | 328 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 2 | 2011 | 697 | 0.090 |
Why?
|
| Medicare | 1 | 2015 | 616 | 0.090 |
Why?
|
| Fellowships and Scholarships | 1 | 2012 | 107 | 0.090 |
Why?
|
| Cerebrospinal Fluid | 1 | 2011 | 29 | 0.080 |
Why?
|
| Cations, Divalent | 1 | 2011 | 24 | 0.080 |
Why?
|
| Ion Transport | 1 | 2011 | 21 | 0.080 |
Why?
|
| Citric Acid | 1 | 2011 | 20 | 0.080 |
Why?
|
| Chelating Agents | 1 | 2011 | 51 | 0.080 |
Why?
|
| Trace Elements | 1 | 2011 | 21 | 0.080 |
Why?
|
| Gene Knockout Techniques | 1 | 2011 | 101 | 0.080 |
Why?
|
| Caprylates | 2 | 2021 | 15 | 0.080 |
Why?
|
| Proteomics | 3 | 2017 | 306 | 0.080 |
Why?
|
| Infusions, Intravenous | 1 | 2011 | 178 | 0.080 |
Why?
|
| Health Services Needs and Demand | 1 | 2012 | 224 | 0.080 |
Why?
|
| DNA, Viral | 1 | 2011 | 236 | 0.080 |
Why?
|
| Pyridines | 1 | 2011 | 117 | 0.080 |
Why?
|
| Fatty Acids | 1 | 2011 | 205 | 0.080 |
Why?
|
| Cytochrome P-450 CYP4A | 1 | 2009 | 1 | 0.080 |
Why?
|
| Young Adult | 5 | 2020 | 4831 | 0.080 |
Why?
|
| Feasibility Studies | 2 | 2022 | 582 | 0.080 |
Why?
|
| Fluorescent Dyes | 1 | 2011 | 204 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2022 | 1018 | 0.070 |
Why?
|
| Diaphragmatic Eventration | 1 | 2008 | 2 | 0.070 |
Why?
|
| Rabbits | 3 | 2016 | 337 | 0.070 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2009 | 134 | 0.070 |
Why?
|
| Intracranial Hemorrhage, Traumatic | 1 | 2008 | 10 | 0.070 |
Why?
|
| Stress, Physiological | 1 | 2011 | 209 | 0.070 |
Why?
|
| Length of Stay | 3 | 2019 | 831 | 0.070 |
Why?
|
| Adolescent | 5 | 2020 | 6377 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2023 | 3355 | 0.070 |
Why?
|
| Oxidation-Reduction | 2 | 2021 | 331 | 0.070 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 1308 | 0.070 |
Why?
|
| Accidental Falls | 1 | 2008 | 129 | 0.070 |
Why?
|
| Organic Cation Transporter 2 | 2 | 2020 | 3 | 0.060 |
Why?
|
| Genotype | 3 | 2015 | 679 | 0.060 |
Why?
|
| Digoxin | 1 | 2025 | 23 | 0.060 |
Why?
|
| California | 2 | 2016 | 177 | 0.060 |
Why?
|
| Nelfinavir | 1 | 2005 | 7 | 0.060 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2017 | 148 | 0.060 |
Why?
|
| Risk Factors | 4 | 2016 | 5441 | 0.060 |
Why?
|
| Creatinine | 2 | 2019 | 134 | 0.060 |
Why?
|
| Genes, MDR | 1 | 2005 | 3 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2019 | 5817 | 0.060 |
Why?
|
| Dextromethorphan | 2 | 2016 | 2 | 0.050 |
Why?
|
| Dextrorphan | 2 | 2016 | 2 | 0.050 |
Why?
|
| Duodenum | 1 | 2024 | 43 | 0.050 |
Why?
|
| HIV Protease Inhibitors | 1 | 2005 | 109 | 0.050 |
Why?
|
| Aminoglycosides | 1 | 2023 | 11 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2025 | 289 | 0.050 |
Why?
|
| Introns | 2 | 2020 | 114 | 0.050 |
Why?
|
| Fluorescein | 1 | 2023 | 13 | 0.050 |
Why?
|
| Fluoresceins | 1 | 2023 | 32 | 0.050 |
Why?
|
| Anions | 1 | 2023 | 34 | 0.050 |
Why?
|
| fas Receptor | 1 | 2023 | 56 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2024 | 2101 | 0.050 |
Why?
|
| Urinary Catheterization | 1 | 2003 | 20 | 0.050 |
Why?
|
| RNA Precursors | 1 | 2004 | 79 | 0.050 |
Why?
|
| Leadership | 1 | 2025 | 214 | 0.050 |
Why?
|
| Methotrexate | 1 | 2023 | 83 | 0.050 |
Why?
|
| Spacecraft | 1 | 2022 | 6 | 0.050 |
Why?
|
| Isothiocyanates | 1 | 2022 | 22 | 0.050 |
Why?
|
| Splenectomy | 1 | 2022 | 39 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2025 | 403 | 0.050 |
Why?
|
| Child | 3 | 2020 | 4681 | 0.050 |
Why?
|
| Aircraft | 1 | 2022 | 18 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 551 | 0.050 |
Why?
|
| Appendectomy | 1 | 2022 | 56 | 0.050 |
Why?
|
| Urinary Tract Infections | 1 | 2003 | 96 | 0.050 |
Why?
|
| Proteinuria | 1 | 2022 | 43 | 0.050 |
Why?
|
| Milk, Human | 2 | 2015 | 97 | 0.040 |
Why?
|
| Fatigue | 1 | 2022 | 115 | 0.040 |
Why?
|
| Cross Infection | 1 | 2003 | 168 | 0.040 |
Why?
|
| Patient Readmission | 2 | 2016 | 446 | 0.040 |
Why?
|
| Blood Proteins | 1 | 2022 | 84 | 0.040 |
Why?
|
| Kinetics | 1 | 2023 | 768 | 0.040 |
Why?
|
| Spleen | 1 | 2022 | 479 | 0.040 |
Why?
|
| Postpartum Period | 2 | 2015 | 197 | 0.040 |
Why?
|
| Cimetidine | 1 | 2020 | 3 | 0.040 |
Why?
|
| Biological Availability | 1 | 2021 | 209 | 0.040 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2020 | 11 | 0.040 |
Why?
|
| Cadmium | 1 | 2019 | 12 | 0.040 |
Why?
|
| Carbohydrate Metabolism | 1 | 2020 | 49 | 0.040 |
Why?
|
| Nevirapine | 1 | 2019 | 8 | 0.040 |
Why?
|
| Pharmacogenomic Testing | 1 | 2019 | 5 | 0.040 |
Why?
|
| PPAR alpha | 1 | 2020 | 34 | 0.040 |
Why?
|
| Historically Controlled Study | 1 | 2019 | 1 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2020 | 155 | 0.040 |
Why?
|
| Uganda | 1 | 2019 | 57 | 0.040 |
Why?
|
| Alkynes | 1 | 2019 | 28 | 0.040 |
Why?
|
| Kenya | 1 | 2019 | 95 | 0.040 |
Why?
|
| Radiography, Abdominal | 1 | 2019 | 27 | 0.040 |
Why?
|
| Cyclopropanes | 1 | 2019 | 55 | 0.040 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2019 | 28 | 0.040 |
Why?
|
| Fluorocarbons | 1 | 2019 | 50 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2020 | 151 | 0.040 |
Why?
|
| Prognosis | 1 | 2023 | 1793 | 0.040 |
Why?
|
| Technology Transfer | 1 | 2018 | 5 | 0.040 |
Why?
|
| Regenerative Medicine | 1 | 2018 | 22 | 0.040 |
Why?
|
| Inflammation | 1 | 2025 | 1186 | 0.040 |
Why?
|
| Collagen Type I | 1 | 2018 | 44 | 0.040 |
Why?
|
| Animal Testing Alternatives | 1 | 2018 | 1 | 0.040 |
Why?
|
| Linear Models | 1 | 2019 | 409 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 207 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 228 | 0.030 |
Why?
|
| Dicumarol | 1 | 2017 | 1 | 0.030 |
Why?
|
| Nephrons | 1 | 2017 | 7 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2018 | 81 | 0.030 |
Why?
|
| Biotransformation | 1 | 2017 | 25 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2019 | 379 | 0.030 |
Why?
|
| Pathology, Molecular | 1 | 2017 | 11 | 0.030 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2017 | 44 | 0.030 |
Why?
|
| Carcinogens | 1 | 2017 | 37 | 0.030 |
Why?
|
| Tissue Scaffolds | 1 | 2018 | 90 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2022 | 734 | 0.030 |
Why?
|
| Endocytosis | 1 | 2018 | 153 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2017 | 130 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2019 | 274 | 0.030 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2017 | 4 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2017 | 7 | 0.030 |
Why?
|
| Aflatoxin B1 | 1 | 2017 | 7 | 0.030 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2017 | 13 | 0.030 |
Why?
|
| Abbreviated Injury Scale | 1 | 2016 | 11 | 0.030 |
Why?
|
| Brain | 1 | 2005 | 1606 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2018 | 403 | 0.030 |
Why?
|
| Macaca fascicularis | 1 | 2016 | 48 | 0.030 |
Why?
|
| Failure to Rescue, Health Care | 1 | 2016 | 5 | 0.030 |
Why?
|
| Species Specificity | 1 | 2016 | 348 | 0.030 |
Why?
|
| Cattle | 1 | 2016 | 321 | 0.030 |
Why?
|
| Geriatrics | 1 | 2016 | 50 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2016 | 107 | 0.030 |
Why?
|
| Genes, Transgenic, Suicide | 1 | 2015 | 2 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2015 | 118 | 0.030 |
Why?
|
| Boston | 1 | 2016 | 260 | 0.030 |
Why?
|
| Dogs | 1 | 2016 | 343 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2015 | 30 | 0.030 |
Why?
|
| Enzyme Stability | 1 | 2015 | 47 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 2077 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2016 | 211 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2015 | 87 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2022 | 1145 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2018 | 1048 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2014 | 235 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2015 | 388 | 0.030 |
Why?
|
| Trauma Severity Indices | 1 | 2013 | 34 | 0.030 |
Why?
|
| Multiple Trauma | 1 | 2013 | 29 | 0.030 |
Why?
|
| Health Services Research | 1 | 2015 | 271 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 938 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2013 | 75 | 0.020 |
Why?
|
| Placenta | 1 | 2013 | 68 | 0.020 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 2012 | 3 | 0.020 |
Why?
|
| Retinoic Acid 4-Hydroxylase | 1 | 2012 | 3 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 1638 | 0.020 |
Why?
|
| Cytochrome P450 Family 2 | 1 | 2012 | 2 | 0.020 |
Why?
|
| Hydroxylation | 1 | 2012 | 10 | 0.020 |
Why?
|
| New England | 1 | 2013 | 271 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2012 | 44 | 0.020 |
Why?
|
| Comorbidity | 1 | 2016 | 1123 | 0.020 |
Why?
|
| Gestational Age | 1 | 2013 | 199 | 0.020 |
Why?
|
| Response Elements | 1 | 2012 | 45 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2016 | 423 | 0.020 |
Why?
|
| Tretinoin | 1 | 2012 | 51 | 0.020 |
Why?
|
| HIV Infections | 1 | 2019 | 965 | 0.020 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2012 | 55 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2019 | 969 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2016 | 877 | 0.020 |
Why?
|
| Logistic Models | 1 | 2016 | 1282 | 0.020 |
Why?
|
| Incidence | 1 | 2016 | 1410 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 1592 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 48 | 0.020 |
Why?
|
| von Willebrand Factor | 1 | 2011 | 10 | 0.020 |
Why?
|
| Lac Operon | 1 | 2011 | 26 | 0.020 |
Why?
|
| Choroid Plexus | 1 | 2011 | 16 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 1618 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 2016 | 0.020 |
Why?
|
| Integrases | 1 | 2011 | 41 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2011 | 199 | 0.020 |
Why?
|
| Pregnancy Trimesters | 1 | 2010 | 10 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 49 | 0.020 |
Why?
|
| Binding Sites | 1 | 2012 | 930 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 1012 | 0.020 |
Why?
|
| Hepacivirus | 1 | 2011 | 139 | 0.020 |
Why?
|
| Fetal Blood | 1 | 2010 | 73 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 1 | 2009 | 6 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2010 | 150 | 0.020 |
Why?
|
| Spodoptera | 1 | 2009 | 28 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2011 | 378 | 0.020 |
Why?
|
| Baculoviridae | 1 | 2009 | 25 | 0.020 |
Why?
|
| Lens, Crystalline | 1 | 2009 | 16 | 0.020 |
Why?
|
| Amidines | 1 | 2009 | 19 | 0.020 |
Why?
|
| Retinal Degeneration | 1 | 2009 | 28 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2011 | 401 | 0.020 |
Why?
|
| Positive-Pressure Respiration | 1 | 2008 | 51 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 713 | 0.020 |
Why?
|
| Time Factors | 1 | 2013 | 3788 | 0.010 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2005 | 1 | 0.010 |
Why?
|
| Acridines | 1 | 2005 | 2 | 0.010 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2005 | 16 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 2005 | 56 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2010 | 1451 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2005 | 193 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2005 | 295 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2005 | 204 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2005 | 424 | 0.010 |
Why?
|
| Catheters, Indwelling | 1 | 2003 | 68 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2005 | 511 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 1613 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2005 | 2149 | 0.010 |
Why?
|